Optical coherence tomography angiography (OCT-A) is a non-invasive, non-dye-based imaging modality that has the potential to enhance our understanding of retinal diseases. While this rapidly advancing imaging modality offers great potential, there is a need for community-wide understanding of the range of technologies and methods for interpreting the images, as well as a need to enhance understanding of images from disease-free eyes for reference when screening for retinal diseases. Importantly, clinical trials have been designed without OCT-A-based endpoints; therefore, caution is required when making treatment decisions based on OCT-A imaging alone. With this in mind, a full understanding of the advantages and limitations of OCT-A will be vital for effective development of the technique within the field of ophthalmology. On behalf of the Vision Academy Steering Committee (sponsored by Bayer), this publication summarizes the views of the authors on the current use of OCT-A imaging and explores its potential for future applications in research and clinical practice.

The role of OCT-A in retinal disease management / F.J. Rodriguez, G. Staurenghi, R. Gale, B. Eldem, A. Hunyor, A. Joussen, A. Koh, J.-. Korobelnik, P. Lanzetta, A. Loewenstein, M. Lovestam-Adrian, R. Navarro, A.A. Okada, I. Pearce, F.J. Rodriguez, S. Wolf, D.T. Wong. - In: GRAEFE'S ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY. - ISSN 0721-832X. - 256:11(2018), pp. 2019-2026. [10.1007/s00417-018-4109-3]

The role of OCT-A in retinal disease management

G. Staurenghi;
2018

Abstract

Optical coherence tomography angiography (OCT-A) is a non-invasive, non-dye-based imaging modality that has the potential to enhance our understanding of retinal diseases. While this rapidly advancing imaging modality offers great potential, there is a need for community-wide understanding of the range of technologies and methods for interpreting the images, as well as a need to enhance understanding of images from disease-free eyes for reference when screening for retinal diseases. Importantly, clinical trials have been designed without OCT-A-based endpoints; therefore, caution is required when making treatment decisions based on OCT-A imaging alone. With this in mind, a full understanding of the advantages and limitations of OCT-A will be vital for effective development of the technique within the field of ophthalmology. On behalf of the Vision Academy Steering Committee (sponsored by Bayer), this publication summarizes the views of the authors on the current use of OCT-A imaging and explores its potential for future applications in research and clinical practice.
Imaging modality; Non-invasive; OCT-A; Optical coherence tomography angiography; Retinal diseases; Diagnostic Techniques, Ophthalmological; Fluorescein Angiography; Humans; Retina; Retinal Diseases; Tomography, Optical Coherence
Settore MED/30 - Malattie Apparato Visivo
2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
10.1007_s00417-018-4109-3.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 2.42 MB
Formato Adobe PDF
2.42 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/704444
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 27
social impact